TH Open: Companion Journal to Thrombosis and Haemostasis最新文献

{"title":"Possible Targets to Reduce Fatigue in Chronic Immune Thrombocytopenia Patients - An Explorative Study.","authors":"Wobke E M van Dijk,&nbsp;Merel M Nap-van der Vlist,&nbsp;Hans Knoop,&nbsp;Roger E G Schutgens","doi":"10.1055/s-0042-1758546","DOIUrl":"https://doi.org/10.1055/s-0042-1758546","url":null,"abstract":"<p><p><b>Background</b>  Fatigue in immune thrombocytopenia (ITP) is frequent and burdensome, but we lack the knowledge to help these patients. <b>Aim</b>  The aim of the study is to explore the role of disease activity and other potentially modifiable factors in fatigue. <b>Method</b>  This cross-sectional study included adult chronic ITP patients ( <i>n</i>  = 59). Univariable linear regression (corrected for confounders) was used to determine the relationship between disease activity (platelet count <30 × 10 ⁹ /L or treatment), disease-specific factors (bleeding symptoms, ferritin), and transdiagnostic factors (FACT-G physical/functional/emotional/social well-being subscales, physical activity level, and vitamin D) and fatigue (Checklist Individual Strength fatigue subscale). Several multivariable models with clustered sets of variables were used to compare the proportion of explained variance of fatigue (adjusted <i>R</i> ² ). <b>Results</b>  Significant relations with moderate effect sizes (>0.50) were found for physical and functional well-being and fatigue, and physical activity and fatigue. Other significant relations with fatigue (effect size 0.30-0.47) included skin and organ bleeding, emotional and social well-being, vitamin D, and disease activity. Notably, the models with disease activity and disease-specific factors explained <20% of the variance in fatigue, while the models with transdiagnostic factors (functioning and physical activity) explained >50%. Vitamin D alone explained 12% of the variance in fatigue. <b>Conclusion</b>  Transdiagnostic (non-disease-specific) rather than disease-specific factors explained a large part of the variance in ITP-related fatigue. Many factors related to fatigue are potentially modifiable and should be investigated as targets for interventions.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/ba/10-1055-s-0042-1758546.PMC9674433.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40713023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records.","authors":"Alex C Spyropoulos,&nbsp;James M Crawford,&nbsp;Yen-Wen Cindy Chen,&nbsp;Veronica Ashton,&nbsp;Alicia K Campbell,&nbsp;Dejan Milentijevic,&nbsp;W Frank Peacock","doi":"10.1055/a-1937-9692","DOIUrl":"https://doi.org/10.1055/a-1937-9692","url":null,"abstract":"<p><p><b>Background</b>  Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some patients experience cardiovascular complications, including thromboembolic events and death. Data are needed to better inform prevention and treatment of these events. This analysis was designed to describe patient characteristics, medication use, thromboembolic events, and all-cause mortality in hospitalized COVID-19 patients in the United States. <b>Methods</b>  This retrospective, observational cohort study identified adults hospitalized with COVID-19 (January 21, 2020-January 07, 2021) in the deidentified Optum COVID-19 Electronic Health Records dataset. Thromboembolic events and all-cause mortality were collected at any time during the variable follow-up period (up to 50 weeks). <b>Results</b>  Of 181,995 COVID-19 patients who met eligibility criteria, 40,524 (22.3%) were hospitalized with COVID-19. Hospitalized patients had a mean age of 63 years and a Quan-Charlson comorbidity index of 1.3. Anticoagulants were used in 89.2% of patients during hospitalization and in 18.7% of postdischarge patients. Of hospitalized patients, 17.6% had a thromboembolic event during the entire follow-up period (mean time to the first event of 15 days), of whom 13.4% had an event during hospitalization; of discharged patients, 4.3% had a thromboembolic event (mean time from discharge to event of 43 days). Death during the follow-up period was reported in 15.0% of patients. <b>Conclusions</b>  In this large, observational cohort study, patients hospitalized with COVID-19 had high rates of thromboembolic events during hospitalization and in the postdischarge period; mortality was also high in this population. Anticoagulant use was common during hospitalization. These findings support further studies to optimize in-hospital and extended prophylaxis for hospitalized COVID-19 patients.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40712932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients.","authors":"Ramiro Núñez,&nbsp;María Teresa Álvarez-Román,&nbsp;Santiago Bonanad,&nbsp;José Ramón González-Porras,&nbsp;Hortensia De La Corte-Rodriguez,&nbsp;Rubén Berrueco,&nbsp;Víctor Jiménez-Yuste","doi":"10.1055/s-0042-1757745","DOIUrl":"https://doi.org/10.1055/s-0042-1757745","url":null,"abstract":"<p><p>Prophylaxis to prevent bleeding is highly recommended for hemophilia patients. The development of new drugs and tools for modeling personalized prophylaxis provides the means for people with hemophilia to lead active lives with a quality of life comparable to that of nonhemophilic individuals. The choice of regimens must be made on a highly individual basis. Unfortunately, reference guides neither always concur in their recommendations nor provide directions to cover all possible scenarios. In this review, a group of experts identify the significant limitations and unmet needs of prophylaxis, taking advantage of their clinical experience in the disease, and supported by a rigorous literature update. To perform a more systematic and comprehensive search for gaps, the main cornerstones that influence decisions regarding prophylactic patterns were first identified. Bleeding phenotype, joint status, physical activity, pharmacokinetics/medication properties, and adherence to treatment were considered as the primary mainstays that should allow physicians guiding prophylaxis to secure the best outcomes. Several challenges identified within each of these topics require urgent attention and agreement. The scores to assess severity of bleeding are not reliable, and lead to no consensus definition of severe bleeding phenotype. The joint status is to be redefined in light of new, more efficient treatments with an agreement to establish one scale as the unique reference for joint health. Further discussion is needed to establish the appropriateness of high-intensity physical activities according to patient profiles, especially because sustaining trough factor levels within the safe range is not always warranted for long periods. Importantly, many physicians do not benefit from the advantages provided by the programs based on population pharmacokinetic models to guide individualized prophylaxis through more efficient and cost-saving strategies. Finally, ensuring correct adherence to long-term treatments may be time-consuming for practitioners, who often have to encourage patients and review complex questionnaires. In summary, we identify five cornerstones that influence prophylaxis and discuss the main conflicting concerns that challenge the proper long-term management of hemophilia. A consensus exercise is warranted to provide reliable guidelines and maximize benefit from recently developed tools that should notably improve patients' quality of life.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/d5/10-1055-s-0042-1757745.PMC9652116.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40712929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.","authors":"Sylvia Haas,&nbsp;Alfredo E Farjat,&nbsp;Karen Pieper,&nbsp;Walter Ageno,&nbsp;Pantep Angchaisuksiri,&nbsp;Henri Bounameaux,&nbsp;Samuel Z Goldhaber,&nbsp;Shinya Goto,&nbsp;Lorenzo Mantovani,&nbsp;Paolo Prandoni,&nbsp;Sebastian Schellong,&nbsp;Alexander G G Turpie,&nbsp;Jeffrey I Weitz,&nbsp;Peter MacCallum,&nbsp;Hugo Ten Cate,&nbsp;Elizaveta Panchenko,&nbsp;Marc Carrier,&nbsp;Carlos Jerjes-Sanchez,&nbsp;Harry Gibbs,&nbsp;Petr Jansky,&nbsp;Gloria Kayani,&nbsp;Ajay K Kakkar","doi":"10.1055/s-0042-1757744","DOIUrl":"https://doi.org/10.1055/s-0042-1757744","url":null,"abstract":"<p><p><b>Background</b>  Direct oral anticoagulants (DOACs) provide a safe, effective alternative to vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via intention-to-treat comparative effectiveness analysis. However, on-treatment analysis is imperative in observational studies because anticoagulation choice and duration are at investigators' discretion. <b>Objectives</b>  The aim of the study is to compare the effectiveness of DOACs and VKAs on 12-month outcomes in VTE patients using on-treatment analysis. <b>Methods</b>  The Global Anticoagulant Registry in the FIELD - VTE (GARFIELD-VTE) is a world-wide, prospective, non-interventional study observing treatment of VTE in routine clinical practice. <b>Results</b>  In total, 8,034 patients received VKAs ( <i>n</i>  = 3,043, 37.9%) or DOACs ( <i>n</i>  = 4,991, 62.1%). After adjustment for baseline characteristics and follow-up bleeding events, and accounting for possible time-varying confounding, all-cause mortality was significantly lower with DOACs than VKAs (hazard ratio: 0.58 [95% confidence interval 0.42-0.79]). Furthermore, patients receiving VKAs were more likely to die of VTE complications (4.9 vs. 2.2%) or bleeding (4.9 vs. 0.0%). There was no significant difference in rates of recurrent VTE (hazard ratio: 0.74 [0.55-1.01]), major bleeding (hazard ratio: 0.76 [0.47-1.24]), or overall bleeding (hazard ratio: 0.87 [0.72-1.05]) with DOACs or VKAs. Unadjusted analyses suggested that VKA patients with active cancer or renal insufficiency were more likely to die than patients treated with DOAC (52.51 [37.33-73.86] vs. 26.52 [19.37-36.29] and 9.97 [7.51-13.23] vs. 4.70 [3.25-6.81] per 100 person-years, respectively). <b>Conclusion</b>  DOACs and VKAs had similar rates of recurrent VTE and major bleeding. However, DOACs were associated with reduced all-cause mortality and a lower likelihood of death from VTE or bleeding compared with VKAs.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40712931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Accuracy of Hestia and Simplified PESI to Predict the Prognosis in Pulmonary Embolism: Systematic Review with Meta-analysis.","authors":"Miguel Palas,&nbsp;Beatriz Valente Silva,&nbsp;Cláudia Jorge,&nbsp;Ana G Almeida,&nbsp;Fausto J Pinto,&nbsp;Daniel Caldeira","doi":"10.1055/a-1942-2526","DOIUrl":"https://doi.org/10.1055/a-1942-2526","url":null,"abstract":"<p><p><b>Introduction</b>  Pulmonary embolism (PE) patients at low risk of early complications may be considered for early discharge or home treatment. Last decades evidence has been growing about the safety of several clinical prediction rules for selecting those patients, such as simplified Pulmonary Embolism Severity Index (sPESI) and Hestia Criteria. The aim of this review was to compare the safety of both strategies regarding 30-days mortality, venous thromboembolism recurrence and major bleeding. <b>Methods</b>  A systematic literature search was conducted using MEDLINE, CENTRAL and Web of Science on 6 ^th January 2022. We searched for studies that applied both Hestia Criteria and sPESI to the same population. Sensitivity, specificity and diagnostic odds ratio were calculated for both stratification rules. Both Hestia and sPESI criteria of low risk were evaluated to set the number of patients that could be misclassified for each 1000 patients with PE. The estimates were reported with their 95% confidence intervals (95%CI). <b>Results</b>  This systematic review included 3 studies. Only mortality data was able to be pooled. Regarding mortality, the sensitivity, specificity and diagnostic odds ratio was 0.923 (95%CI: 0.843-0.964), 0.338 (95%CI: 0.262-0.423) and 6.120 (95%CI: 2.905-12.890) for Hestia Criteria; and 0.972 (95%CI: 0.917-0.991), 0.269 (95%CI: 0.209-0.338) and 12.738 (95%CI: 3.979-40.774) for sPESI score. The negative predictive values were higher than 0.977. The risk of misclassification of high-risk patients in low risk was 5 (95%CI: 3-11) with Hestia and 2 (95%CI: 1-6) with sPESI, for each 1000 patients with PE in terms of mortality. <b>Conclusion</b>  The risk of misclassification of patients presenting with low-risk pulmonary embolism with the intent of early discharge or home treatment with both Hestia Criteria and sPESI score is low and these data supports methods for this purpose.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40712930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of von Willebrand Disease in the \"Heart of Europe\".","authors":"Inge Vangenechten,&nbsp;Petr Smejkal,&nbsp;Jiri Zavrelova,&nbsp;Ondrej Zapletal,&nbsp;Alexander Wild,&nbsp;Jan Jacques Michiels,&nbsp;Zwi Berneman,&nbsp;Jan Blatny,&nbsp;Angelika Batorova,&nbsp;Tatiana Prigancova,&nbsp;Miroslav Penka,&nbsp;Alain Gadisseur","doi":"10.1055/s-0042-1757635","DOIUrl":"https://doi.org/10.1055/s-0042-1757635","url":null,"abstract":"<p><p><b>Background</b>  von Willebrand disease (VWD) is a genetic bleeding disorder caused by defects of von Willebrand factor (VWF), quantitative (type 1 and 3) or qualitative (type 2). The laboratory phenotyping is heterogenic making diagnosis difficult. <b>Objectives</b>  Complete laboratory analysis of VWD as an expansion of the previously reported cross-sectional family-based VWD study in the Czech Republic (BRNO-VWD) and Slovakia (BRA-VWD) under the name \"Heart of Europe,\" in order to improve the understanding of laboratory phenotype/genotype correlation. <b>Patients and Methods</b>  In total, 227 suspected VWD patients were identified from historical records. Complete laboratory analysis was established using all available assays, including VWF multimers and genetic analysis. <b>Results</b>  A total of 191 patients (from 119 families) were confirmed as having VWD. The majority was characterized as a type 1 VWD, followed by type 2. Multimeric patterns concordant with laboratory phenotypes were found in approximately 83% of all cases. A phenotype/genotype correlation was present in 84% (77% type 1, 99% type 2, and 61% type 3) of all patients. Another 45 candidate mutations (23 novel variations), not found in the initial study, could be identified (missense 75% and truncating 24%). An exon 1-3 gene deletion was identified in 14 patients where no mutation was found by direct DNA sequencing, increasing the linkage up to 92%, overall. <b>Conclusion</b>  This study provides a cross-sectional overview of the VWD population in a part of Central Europe. It is an addition to the previously published BRNO-VWD study, and provides important data to the International Society of Thrombosis and Haemostasis/European Association for Haemophilia and Allied Disorders VWD mutation database with identification of novel causal mutations.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40431051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does High-Dose Thromboprophylaxis Improve Outcomes in COVID-19 Patients? A Meta-analysis of Comparative Studies.","authors":"Maha A T Elsebaie,&nbsp;Binav Baral,&nbsp;Mai Elsebaie,&nbsp;Trilok Shrivastava,&nbsp;Catherine Weir,&nbsp;Dennis Kumi,&nbsp;Noah W Birch","doi":"10.1055/a-1930-6492","DOIUrl":"https://doi.org/10.1055/a-1930-6492","url":null,"abstract":"<p><p><b>Background</b>  Thromboembolism remains a detrimental complication of novel coronavirus disease (COVID-19) despite the use of prophylactic doses of anticoagulation <b>Objectives</b>  This study aimed to compare different thromboprophylaxis strategies in COVID-19 patients <b>Methods</b>  We conducted a systematic database search until June 30, 2022. Eligible studies were randomized (RCTs) and nonrandomized studies that compared prophylactic to intermediate or therapeutic doses of anticoagulation in adult patients with COVID-19, admitted to general wards or intensive care unit (ICU). Primary outcomes were mortality, thromboembolism, and bleeding events. Data are analyzed separately in RCTs and non-RCTs and in ICU and non-ICU patients. <b>Results.</b>  We identified 682 studies and included 53 eligible studies. Therapeutic anticoagulation showed no mortality benefit over prophylactic anticoagulation in four RCTs (odds ratio [OR] = 0.67, 95% confidence interval [CI], 0.18-2.54). Therapeutic anticoagulation didn't improve mortality in ICU or non-ICU patients. Risk of thromboembolism was significantly lower among non-ICU patients who received enhanced (therapeutic/intermediate) anticoagulation (OR = 0.21, 95% CI, 0.06-0.74). Two additional RCTs (Multiplatform Trial and HEP-COVID), not included in quantitative meta-analysis, analyzed non-ICU patients, and reported a similar benefit with therapeutic-dose anticoagulation. Therapeutic anticoagulation was associated with a significantly higher risk of bleeding events among non-randomized studies (OR = 3.45, 95% CI, 2.32-5.13). Among RCTs, although patients who received therapeutic-dose anticoagulation had higher numbers of bleeding events, these differences were not statistically significant. Studies comparing prophylactic and intermediate-dose anticoagulation showed no differences in primary outcomes. <b>Conclusion</b>  There is a lack of mortality benefit with therapeutic-dose over prophylactic-dose anticoagulation in ICU and non-ICU COVID-19 patients. Therapeutic anticoagulation significantly decreased risk of thromboembolism risk in some of the available RCTs, especially among non-ICU patients. This potential benefit, however, may be counter balanced by higher risk of bleeding. Individualized assessment of patient's bleeding risk will ultimately impact the true clinical benefit of anticoagulation in each patient. Finally, we found no mortality or morbidity benefit with intermediate-dose anticoagulation.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40431053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors.","authors":"Stephan N M C G Oliveira,&nbsp;Ana M F Tovar,&nbsp;Francisco F Bezerra,&nbsp;Adriana A Piquet,&nbsp;Nina V Capillé,&nbsp;Paloma S Santos,&nbsp;Eduardo Vilanova,&nbsp;Paulo A S Mourão","doi":"10.1055/a-1946-0325","DOIUrl":"https://doi.org/10.1055/a-1946-0325","url":null,"abstract":"<p><p>Heparin has already been found in a variety of animal tissues but only few of them became effective sources for production of pharmaceutical preparations. Here, we correlate physical-chemical features and anticoagulant activities of structurally similar heparins employed in the past (from bovine lung, HBL), in the present (from porcine intestine, HPI) and in development for future use (from ovine intestine, HOI). Although they indeed have similar composition, our physical-chemical analyses with different chromatography and spectrometric techniques show that both HOI and HBL have molecular size notably lower than HPI and that the proportions of some of their minor saccharide components can vary substantially. Measurements of anticoagulant activities with anti-FIIa and anti-FXa assays confirmed that HPI and HOI have potency similar each other but significantly higher than HBL. Such a lower activity of HBL has been attributed to its reduced molecular size. Considering that HOI also has reduced molecular size, we find that its increased anticoagulant potency might result from an improved affinity to antithrombin (three times higher than HBL) promoted by the high content of <i>N</i> ,3,6-trisulfated glucosamine units, which in turn are directly involved in the heparin-antithrombin binding. Therefore, the anticoagulant activity of different heparins is driven by a balance between different physical-chemical components, especially molecular size and fine-tuning composition. Although such minor but relevant chemical differences reinforce the concept that heparins from different animal sources should indeed be considered as distinct drugs, HOI could be approved for interchangeable use with the gold standard HPI and as a suitable start material for producing new LMWHs.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40713019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.","authors":"Alex C Spyropoulos,&nbsp;Gary E Raskob,&nbsp;Theodore E Spiro,&nbsp;Wentao Lu,&nbsp;Yoriko De Sanctis,&nbsp;John Albanese,&nbsp;Alexandre Mebazaa,&nbsp;Elliot S Barnathan","doi":"10.1055/a-1926-2489","DOIUrl":"https://doi.org/10.1055/a-1926-2489","url":null,"abstract":"<p><p>This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for heart failure or a history of heart failure and a lower risk of bleeding. A significant 36% reduction in the composite endpoint of asymptomatic proximal deep vein thrombosis (DVT) in the lower extremity, symptomatic DVT in the lower extremity (proximal or distal), symptomatic nonfatal pulmonary embolism, and venous thromboembolism-related death was observed with rivaroxaban. Major bleeding was low in both groups and not significantly increased with rivaroxaban.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40431052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apixaban Prophylactic Anticoagulation in Patients with Nephrotic Syndrome.","authors":"Tess Van Meerhaeghe,&nbsp;Alexandre Cez,&nbsp;Karine Dahan,&nbsp;Emmanuel Esteve,&nbsp;Ismail Elalamy,&nbsp;Jean Jacques Boffa,&nbsp;Eleonore Ponlot","doi":"10.1055/a-1920-6224","DOIUrl":"https://doi.org/10.1055/a-1920-6224","url":null,"abstract":"<p><p><b>Background</b>  Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TEs), due to hemostatic derangements. The use of direct oral anticoagulants (DOACs) in the prevention of TE has not been studied intensively in patients suffering from NS. <b>Methods</b>  The method included retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thromboprophylaxis. It is an uncontrolled, single-center study. <b>Results</b>  We identified 27 patients treated with apixaban for the prevention of TEs, in the context of NS. During follow-up, apixaban minimal blood concentration (trough level; Cmin) and maximum blood concentration (Cmax) levels were measured. The mean duration of the anticoagulant treatment was 153 days (±132). Patients were followed for a mean of 14.7 months (±8.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in a lupus membranous nephropathy context. One patient developed PE approximately 2 months after the introduction of apixaban treatment. No minor or major bleeding events were noticed. <b>Conclusion</b>  The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had a reduced risk of venous and arterial TEs compared with patients previously described in the literature, without increased risk of bleeding.</p>","PeriodicalId":22238,"journal":{"name":"TH Open: Companion Journal to Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40431050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}